Takeda pulls the plug on orteronel for prostate cancer

Citing a failure to demonstrate a statistically significant improvement in overall survival (OS), Takeda Pharmaceutical Company Ltd (TKPYY) terminates its orteronel development program for prostate cancer. The firm's decision is not unexpected considering its disclosure in 2013 that an interim analysis of the results of the Phase 3 ELM-PC5 clinical trial showed that orteronel would be unlikely to meet its primary endpoint of OS compared to placebo.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs